SABCS Conference Coverage
Filter News By:

Featured Conference News

SABCS 2020: Salvage Chemo Appears Ineffective For High Risk, ER-Positive, HER2-Negative Breast Cancer

December 11 2020 - In patients with estrogen receptor (ER)-positive, HER2-negative breast cancer that is resistant to neoadjuvant endocrine therapy, the use of salvage neoadjuvant chemotherapy is not likely to induce a complete or near complete response, according to findings presented at the 2020 San Antonio Breast Cancer Symposium.

SABCS 2020: Pembrolizumab Plus Chemo Continues to Shine in New KEYNOTE-355 Analysis

December 11 2020 - Pembrolizumab plus chemotherapy improved the progression-free survival, overall response rate, durable complete remission, and duration of response for patients with locally recurrent, unresectable or metastatic triple negative breast cancer (TNBC) with tumors expressing PD-L1 and a combined positive score (CPS) of 10 or more, according to new findings from the KEYNOTE-355 trial.

SABCS 2020: Novel Oral Taxane Demonstrates Efficacy in CONTESSA Trial

December 11 2020 - An all-oral regimen of tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival (PFS) and other endpoints, compared with capecitabine alone, in patients with HER2-negative, hormone receptor (HR)-positive metastatic breast cancer (MBC), according to findings from the CONTESSA trial.

SABCS 2020: Some Older Women Can Safely Skip Radiation After Breast Conserving Surgery

December 10 2020 - Omitting radiation after breast-conserving surgery may not impact 10-year survival rates in women 65 years or older with hormone receptor-positive, early invasive breast cancer, suggest long-term follow up results from the PRIME II trial. The findings were presented at the 2020 San Antonio Breast Cancer Symposium.

SABCS 2020: Women Undergoing Mastectomy and Reconstruction Surgery Face Addiction Risk

December 10 2020 - Women who undergo mastectomy and reconstruction surgery may face the risk of long-term dependence on opioids and sedative-hypnotic drugs, according to research presented at the 2020 San Antonio Breast Cancer Symposium.

SABCS 2020: Palbociclib Did Not Improve Disease-Free Survival in PENELOPE-B Trial

December 10 2020 - The addition of 1 year of the CDK4/6 inhibitor palbociclib to endocrine therapy did not improve invasive disease-free survival (IDFS) in hormone receptor (HR)-positive, HER2-negative primary breast cancer in patients at high risk for relapse following neoadjuvant chemotherapy, according to results from the PENELOPE-B trial.

SABCS 2020: Abemaciclib Shines in monarchE Trial

December 09 2020 - Compared to endocrine therapy alone, abemaciclib plus endocrine therapy improves invasive disease-free survival (IDFS) in patients with high-risk, node-positive, early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer, according to extended follow-up data from the phase 3 monarchE trial presented at the 2020 San Antonio Breast Cancer Symposium.

SABCS 2020: RxPONDER Trial Identifies Women with Breast Cancer Who Can Skip Chemotherapy

December 09 2020 - Postmenopausal women with early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer who receive adjuvant endocrine therapy and have an Oncotype Dx test recurrence score of 0 to 25 can safely avoid chemotherapy.

Featured News
View all
More News
(Fred Hutch) Dec 18, 2020 - Hutch scientists share findings on treatment, imaging, CAR T therapy, COVID-19’s impact on cancer patients and more.
(Morningstar) Dec 17, 2020 - Evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine benefit irrespective of clinical risk for HR+ early-stage breast cancer patients was highlighted during a Spotlight...
(MedPage Today) Dec 13, 2020 - Adding the investigational agent ipatasertib to paclitaxel failed to improve progression-free survival (PFS) in patients with PIK3CA/AKT1/PTEN-altered advanced triple-negative breast cancer, a researcher...
(Puma) Dec 11, 2020 - Puma Biotechnology, Inc., a biopharmaceutical company, presented efficacy and safety outcomes in a subgroup of patients from the NALA trial who had central nervous system (CNS) metastases at baseline, with a...
(Odonate) Dec 11, 2020 - CONTESSA achieved primary endpoint – tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival (PFS) versus the approved dose of capecitabine alone (hazard ratio=0.716;...
(SABCS 2020) Dec 11, 2020 - One of the enduring problems in treating ER+ breast cancer is its persistent tendency to recur. HER+ and triple negative breast cancers usually recur within the first few years after treatment, but ER+ cancers...
(Gilead) Dec 10, 2020 - Gilead Sciences, Inc. is presenting new data from the Phase 3 ASCENT trial of Trodelvy® (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer (mTNBC) at the 2020 San Antonio Breast Cancer...
(SABCS 2020) Dec 11, 2020 - Recovering from breast cancer means more than good clinical outcomes. The overarching goal is good quality of life, which means balancing clinical outcomes with treatment toxicities while preserving a positive...
(OBR) Dec 11, 2020 - Pembrolizumab plus chemotherapy improved the progression-free survival, overall response rate, durable complete remission, and duration of response for patients with locally recurrent, unresectable or metastatic triple...
(OBR) Dec 11, 2020 - In patients with estrogen receptor (ER)-positive, HER2-negative breast cancer that is resistant to neoadjuvant endocrine therapy, the use of salvage neoadjuvant chemotherapy is not likely to induce a complete or near...

OBR Tweets

Dec 06
Stephen Ansell, MD, PhD, of @MayoCancerCare on options for lymphoma patients who are refractory to CAR T-cell treat… https://t.co/0in19JpTFM

Dec 06
@TomBmt133 of @UCSFCancer considers the significance of the IKEMA study #ASH20 https://t.co/hPGQ0EeLgx

Dec 06
@MichaelDJain on immunotherapy treatment trends in the management of aggressive lymphomas @MoffittNews #ASH20 https://t.co/9XpyqMU0X3

Dec 06
Bhavana Bhatnagar, DO, regarding data on racial disparities in the treatment of AML from #ASH20 https://t.co/IWQOcPAupf

Sep 24
Cristina Suárez, MD, of @vallhebron offers opinion on whether the CheckMate 9ER trial is practice-changing #ESMO20 https://t.co/6m8UCjJPxE

Sep 24
Andrew Schmidt, MD, @dr_aschmidt of @DanaFarber regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented a… https://t.co/tbmT0twPFA

Sep 24
Erika Hamilton, MD, @ErikaHamilton9 of @SarahCannonDocs regarding the Phase III monarchE trial presented at #ESMO20 https://t.co/AiqtvpEZ7u

Sep 24
Giuseppe Giaccone, PhD, MD, of @WeillCornell regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCL… https://t.co/D5Su3qEkbb

Sep 24
Pasi A. Jänne, MD, PhD, of @DanaFarber shares data from #ESMO20 investigating mobocertinib https://t.co/idTloLVyBj

Sep 24
Maha Hussain, MD, of @LurieCancer provides perspective on the Phase III PROfound study presented at #ESMO20 https://t.co/NerWJUf67S